The DOI matches its Crossref record; 131 of the 132 references it cites were found in a registry or an index.
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Open accessAbstract
The cancer stem cell (SC) theory proposes that a population of SCs serves as the driving force behind fundamental tumor processes, including metastasis, recurrence, and resistance to therapy. The standard of care for patients with stage III and high-risk stage II colorectal cancer (CRC) includes surgery and adjuvant chemotherapy. Fluoropyrimidines and their combination with oxaliplatin increased the cure rates, being able to eradicate the occult metastatic SC in a fraction of patients. The treatment for unresectable metastatic CRC is based on chemotherapy, antibodies to VEGF and EGFR, and tyrosine-kinase inhibitors. Immunotherapy is used in MSI-H tumors. Currently used drugs target dividing cells and, while often effective at debulking tumor mass, these agents have largely failed to cure metastatic disease. SCs are generated either due to genetic and epigenetic alterations in stem/progenitor cells or to the dedifferentiation of somatic cells where diverse signaling pathways such as Wnt/β-catenin, Hedgehog, Notch, TGF-β/SMAD, PI3K/Akt/mTOR, NF-κB, JAK/STAT, DNA damage response, and Hippo-YAP play a key role. Anti-neoplastic treatments could be improved by elimination of SCs, becoming an attractive target for the design of novel agents. Here, we present a review of clinical trials assessing the efficacy of targeted treatment focusing on these pathways in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, colorectal CSCs exhibit significant cellular plasticity in that they can transition between stem like and differentiated states, which further increases tumor heterogeneity and escape from therapeutic targeting [72].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“Regorafenib is a multitargeted kinase inhibitor approved for the treatment of patients with metastatic CRC (mCRC) who are refractory to standard chemotherapy [18].”
BackgroundCrypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
Yu, H., Lin, L., Zhang, Z., Zhang, H., & Hu, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00312-6 · Cited by 2,135
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T. A., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,136
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties
Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., Canli, O., Heijmans, J., Huels, D. J., Moreaux, G., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.012 · Cited by 1,068
Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4
Todaro, M., Alea, M. P., Di Stefano, A. B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, C., Russo, A., Gulotta, G., Medema, J. P., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.001 · Cited by 1,039
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
Wnt signaling in colorectal cancer: Pathogenic role and therapeutic target
Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q., & Xu, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01616-7 · Cited by 857
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Oskarsson, T., Batlle, E., & Massagué, J. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.002 · Cited by 708
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Dylla, S. J., Beviglia, L., Park, I.-K., Chartier, C., Raval, J., Ngan, L., Pickell, K., Aguilar, J., Lazetic, S., Smith-Berdan, S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002428 · Cited by 589
The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
Stopa, N., Krebs, J. E., & Shechter, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1847-9 · Cited by 513
Hainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
Quantitative evidence for early metastatic seeding in colorectal cancer
Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J., Suarez, C. J., Berghoff, A. S., Cremolini, C., Falcone, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0423-x · Cited by 490
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
DNA-Damage Response in Tissue-Specific and Cancer Stem Cells
Blanpain, C., Mohrin, M., Sotiropoulou, P. A., & Passegué, E. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.012 · Cited by 348
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo‐Bermejo, M., Cruz, C., Llop‐Guevara, A., Gutiérrez‐Enríquez, S., Ducy, M., Ibrahim, Y. H., Gris‐Oliver, A., Pellegrino, B., Bruna, A., Guzmán, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809172 · Cited by 268
Howells, L. M., Iwuji, C. O. O., Irving, G. R. B., Barber, S., Walter, H., Sidat, Z., Griffin-Teall, N., Singh, R., Foreman, N., Patel, S. R., et al. (2019) · The Journal of Nutrition · doi:10.1093/jn/nxz029 · Cited by 245
Wnt Signaling and Drug Resistance in Cancer
Zhong, Z., & Virshup, D. M. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.117978 · Cited by 241
Grillet, F., Bayet, E., Villeronce, O., Zappia, L., Lagerqvist, E. L., Lunke, S., Charafe-Jauffret, E., Pham, K., Molck, C., Rolland, N., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311447 · Cited by 215
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Mengie Ayele, T., Tilahun Muche, Z., Behaile Teklemariam, A., Bogale, A., & Chekol Abebe, E. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s353489 · Cited by 213
Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer
Soleimani, A., Rahmani, F., Ferns, G. A., Ryzhikov, M., Avan, A., & Hassanian, S. M. (2020) · Gene · doi:10.1016/j.gene.2019.144132 · Cited by 203
Cheung, P., Xiol, J., Dill, M. T., Yuan, W.-C., Panero, R., Roper, J., Osorio, F. G., Maglic, D., Li, Q., Gurung, B., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.07.003 · Cited by 189
Ng, K., Nimeiri, H. S., McCleary, N. J., Abrams, T. A., Yurgelun, M. B., Cleary, J. M., Rubinson, D. A., Schrag, D., Miksad, R., Bullock, A. J., et al. (2019) · JAMA · doi:10.1001/jama.2019.2402 · Cited by 184
Berlin, J., Bendell, J. C., Hart, L. L., Firdaus, I., Gore, I., Hermann, R. C., Mulcahy, M. F., Zalupski, M. M., Mackey, H. M., Yauch, R. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1800 · Cited by 181
A Review on Notch Signaling and Colorectal Cancer
Tyagi, A., Sharma, A. K., & Damodaran, C. (2020) · Cells · doi:10.3390/cells9061549 · Cited by 179
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Jonker, D. J., Nott, L., Yoshino, T., Gill, S., Shapiro, J., Ohtsu, A., Zalcberg, J., Vickers, M. M., Wei, A. C., Gao, Y., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30009-8 · Cited by 172
Smith, D. C., Eisenberg, P. D., Manikhas, G., Chugh, R., Gubens, M. A., Stagg, R. J., Kapoun, A. M., Xu, L., Dupont, J., & Sikic, B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1373 · Cited by 162
Yamazaki, T., Gunderson, A. J., Gilchrist, M., Whiteford, M. H., Kiely, M. X., Hayman, A. V., O’Brien, D. P., Ahmad, R., Manchio, J. V., Fox, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00446-6 · Cited by 158
A phase II study of RO4929097 in metastatic colorectal cancer
Strosberg, J., Yeatman, T. J., Weber, J., Coppola, D., Schell, M. J., Han, G., Almhanna, K., Kim, R. D., Valone, T., Jump, H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.056 · Cited by 152
TGF-beta signalling in colon carcinogenesis
Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A. I., Nikiteas, N. I., & Papavassiliou, A. G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.041 · Cited by 152
Liu, Y., Wang, G., Yu, Y., Mei, Z., Liang, Z., Cui, A., Wu, T., Liu, C.-Y., & Cui, L. (2015) · Oncogene · doi:10.1038/onc.2015.342 · Cited by 152
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
Feustel, K., & Falchook, G. S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-1 · Cited by 152
Vitamin D Is a Multilevel Repressor of Wnt/b-Catenin Signaling in Cancer Cells
Larriba, M. J., González‐Sancho, J. M., Barbáchano, A., Niell, N., Ferrer‐Mayorga, G., & Múñoz, A. (2013) · Cancers · doi:10.3390/cancers5041242 · Cited by 148
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0776-6 · Cited by 147 · cited 2×
“PI3KCA mutations are present in 13% of mCRC cases and are associated with right-sided tumors, older patients, and poor prognosis [58–60].”
BackgroundDynamic and adaptive cancer stem cell population admixture in colorectal neoplasia
Vázquez, E. G., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., Schenck, R. O., Wouters, V. M., Wirapati, P., Gilroy, K. L., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.07.008 · Cited by 140
An oncogenic phenoscape of colonic stem cell polarization
Qin, X., Rodriguez, F. C., Sufi, J., Vlckova, P., Claus, J., & Tape, C. J. (2023) · Cell · doi:10.1016/j.cell.2023.11.004 · Cited by 136
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D., Lee, S., Han, S., Kim, M., Kim, T.-M., Kim, T., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 128
Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 126
Zeligs, K., Neuman, M. K., & Annunziata, C. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1374 · Cited by 126
Nakano, M., Kikushige, Y., Miyawaki, K., Kunisaki, Y., Mizuno, S., Takenaka, K., Tamura, S., Okumura, Y., Ito, M., Ariyama, H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0480-0 · Cited by 125
Pintova, S., Dharmupari, S., Moshier, E. L., Zubizarreta, N. J., Ang, C., & Holcombe, R. F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03886-3 · Cited by 123
Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1320-y · Cited by 117
MacKay, H. J., Hedley, D. W., Major, P. P., Townsley, C. A., MacKenzie, M. J., Vincent, M. D., Degendorfer, P., Tsao, M., Nicklee, T., Birle, D. C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0081 · Cited by 109
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 105
Bendell, J. C., Kurkjian, C. D., Infante, J. R., Bauer, T. M., Burris, H. A., Greco, F. A., Shih, K. C., Thompson, D. S., Lane, C. M., Finney, L. H., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0218-6 · Cited by 101
Ebrahimi, N., Afshinpour, M., Fakhr, S. S., Kalkhoran, P. G., Shadman-Manesh, V., Adelian, S., Beiranvand, S., Rezaei‐Tazangi, F., Khorram, R., Hamblin, M. R., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103920 · Cited by 101
Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers
Arakawa, H., Hayashl, N., Nagase, H., Ogawa, M., & Nakamura, Y. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.4.565 · Cited by 99
Tabernero, J. M., van Geel, R. M. J. M., Guren, T. K., Yaeger, R. D., Spreafico, A., Faris, J. E., Yoshino, T., Yamada, Y., Kim, T. W., Bendell, J. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3544 · Cited by 99
Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0530-5 · Cited by 98
Manic, G., Signore, M., Sistigu, A., Russo, G., Corradi, F., Siteni, S., Musella, M., Vitale, S., De Angelis, M. L., Pallocca, M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-312623 · Cited by 98
PI 3K/Akt/ mTOR pathway dual inhibitor BEZ 235 suppresses the stemness of colon cancer stem cells
Chen, J., Shao, R., Li, F., Monteiro, M. J., Liu, J., Xu, Z. P., & Gu, W. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12493 · Cited by 97
Oh, J., Barve, M. A., Matthews, C. M., Koon, E. C., Heffernan, T. P., Fine, B. A., Grosen, E. A., Bergman, M. K., Fleming, E. L., DeMars, L. R., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.09.018 · Cited by 96
Pant, S., Jones, S. F., Kurkjian, C. D., Infante, J. R., Moore, K. N., Burris, H. A., McMeekin, D. S., Benhadji, K. A., Patel, B. K. R., Frenzel, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.021 · Cited by 94
Kawazoe, A., Kuboki, Y., Shinozaki, E., Hara, H., Nishina, T., Komatsu, Y., Yuki, S., Wakabayashi, M., Nomura, S., Sato, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1803 · Cited by 93 · cited 1×
“The DCR was 45% and the median response duration was 9 months in MSS mCRC [92].”
BackgroundDamodaran, S., Zhao, F., Deming, D. A., Mitchell, E. P., Wright, J. J., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01648 · Cited by 87
Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M. J., Abraham, J. P., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab169 · Cited by 85
Leichman, L., Groshen, S. G., O’Neil, B. H., Messersmith, W. A., Berlin, J. D., Chan, E. W., Leichman, C. G., Cohen, S. J., Cohen, D. J., Lenz, H., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0319 · Cited by 83
Hedgehog signaling pathway in colorectal cancer: function, mechanism, and therapy
Wu, C., Zhu, X., Liu, W., Ruan, T., & Tao, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139639 · Cited by 82
The strategies to cure cancer patients by eradicating cancer stem-like cells
Mai, Y., Su, J., Yang, C., Xia, C., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01867-y · Cited by 82
Sahebjam, S., Bedard, P. L., Castonguay, V., Chen, Z., Reedijk, M., Liu, G., Cohen, B. L., Zhang, W.-J., Clarke, B. A., Zhang, T., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.380 · Cited by 75
Malla, S. B., Byrne, R. M., Lafarge, M. W., Corry, S. M., Fisher, N. C., Tsantoulis, P. K., Mills, M. L., Ridgway, R. A., Lannagan, T. R. M., Najumudeen, A. K., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01654-5 · Cited by 73
Plastic persisters: revival stem cells in colorectal cancer
Tape, C. J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.003 · Cited by 72
Chen, Y., Chen, M., & Deng, K. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5472 · Cited by 71
Tabernero, J. M., Cutsem, E. V., Garralda, E., Tai, D. W.-M., de Braud, F., Geva, R., van Bussel, M. T. J., Dotti, K. F., Élez, E., Miguel, M. J. D., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad007 · Cited by 70
Pishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch‐Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31309 · Cited by 69
Gorbunova, V. A., Beck, J. T., Hofheinz, R., Alfonso, P. G., Nechaeva, M., Gracián, A. C., Mangel, L., Élez, E., Deming, D. A., Ramanathan, R. K., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0343-z · Cited by 58
Wu, F. T. H., Man, S., Xu, P., Chow, A., Paez-Ribes, M., Lee, C. R., Pirie-Shepherd, S. R., Emmenegger, U., & Kerbel, R. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0888 · Cited by 58
A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Park, W.-J., & Kim, M. J. (2023) · Cells · doi:10.3390/cells12081110 · Cited by 57
Chen, E. X., Jonker, D. J., Siu, L. L., McKeever, K., Keller, D., Wells, J., Hagerman, L., & Seymour, L. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0351-x · Cited by 56
Cancer Stem Cells, Pluripotency, and Cellular Heterogeneity
Atlasi, Y., Looijenga, L. H. J., & Fodde, R. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00013-5 · Cited by 55
Fogelman, D. R., Cubillo, A., Alfonso, P. G., Mirón, M. L. L., Nemunaitis, J. J., Flora, D. B., Borg, C., Mineur, L., Viéitez, J. M., Cohn, A. L., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1703 · Cited by 54
McRee, A. J., Sanoff, H. K., Carlson, C. A., Ivanova, A., & O’Neil, B. H. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0298-3 · Cited by 54
Bauer, T. M., Santoro, A., Lin, C., Garrido‐Laguna, I., Joerger, M., Greil, R., Spreafico, A., Yau, T. C. C., Goebeler, M.-E., Hütter‐Krönke, M. L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007353 · Cited by 53
Tolcher, A. W., Lakhani, N. J., McKean, M. A., Lingaraj, T., Victor, L., Sánchez-Martín, M., Kacena, K. A., Malek, K. S., & Santillana, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps3168 · Cited by 52
Cai, M., Xu, X., Yan, S.-L., Sun, Z., Yin, Y., Wang, B., & Tu, Y. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0836-x · Cited by 46
Williams, S. M. G., Kuznicki, A. M., Andrade, P. B., Dolinski, B. M., Elbi, C., O’Hagan, R. C., & Toniatti, C. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0162-8 · Cited by 46
PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades
Yan, Y., Zhao, P., Wang, Z., Liu, Z., Wang, Z., Zhang, J., Ding, Y., Hua, X., & Yu, L. (2021) · Aging · doi:10.18632/aging.202407 · Cited by 44
Arcaroli, J. J., Tai, W., McWilliams, R. R., Bagby, S. M., Blatchford, P. J., Varella‐Garcia, M., Purkey, A., Quackenbush, K. S., Song, E., Pitts, T. M., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29676 · Cited by 44
Hedgehog signaling pathway inhibitors: an updated patent review (2015–present)
Quaglio, D., Infante, P., Marcotullio, L. D., Botta, B., & Mori, M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1730327 · Cited by 44
Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer
Hartley, A.-V., Wang, B., Jiang, G., Han, W., Sun, M., Prabhu, L., Martin, M., Safa, A. R., Sun, S., Liu, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103684 · Cited by 44
Shah, M. A., Yoshino, T., Tebbutt, N. C., Grothey, A. F., Tabernero, J. M., Xu, R., Cervantes, A. M. R., Oh, S. C., Yamaguchi, K., Fakih, M., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.002 · Cited by 43
Bowles, D. W., Kochenderfer, M., Cohn, A., Sideris, L., Nguyen, N., Cline-Burkhardt, V., Schnadig, I., Choi, M., Nabell, L., Chaudhry, A., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.004 · Cited by 42
Abbasian, M., Mousavi, E., Arab‐Bafrani, Z., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27619 · Cited by 42
Correction: Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Dylla, S. J., Beviglia, L., Park, I.-K., Chartier, C., Raval, J., Ngan, L., Pickell, K., Aguilar, J., Lazetic, S., Smith‐Berdan, S., et al. (2008) · PLoS ONE · doi:10.1371/annotation/2aa6a20a-e63c-49b6-aeea-aae62435617f · Cited by 42
Simonelli, M., Zucali, P. A., Santoro, A., Thomas, M. B., de Braud, F., Borghaei, H., Berlin, J. D., Denlinger, C. S., Noberasco, C., Rimassa, L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw240 · Cited by 41
Wheatley‐Price, P., Chu, Q. S.-C., Bonomi, M., Seely, J. M., Gupta, A. K., Goss, G. D., Hilton, J. F., Feld, R. D., Lee, C. W., Goffin, J. R., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.024 · Cited by 39
IKKα plays a major role in canonical NF-κB signalling in colorectal cells
Prescott, J. A., Balmanno, K., Mitchell, J. P., Okkenhaug, H., & Cook, S. J. (2022) · Biochemical Journal · doi:10.1042/bcj20210783 · Cited by 37
Bauzone, M., Souidi, M., Dessein, A., Wisztorski, M., Vincent, A., Gimeno, J., Monté, D., SEUNINGEN, I. V., Gespach, C. P., & Huet, G. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0462 · Cited by 37
Spira, A. I., Wertheim, M. S., Kim, E. J.-H., Tan, B. R., Lenz, H., Nikolinakos, P. G., Rich, P. L., Jehl, G., Machl, A. W., Ito, R., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac254 · Cited by 35
Sastre, J., de la Orden, V., Martínez, A., Bando, I., Balbı́n, M., Bellosillo, B., Palanca, S., Peligros, M. I., Mediero-Valeros, B., Llovet, P., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.014 · Cited by 31
Manic, G., Musella, M., Corradi, F., Sistigu, A., Vitale, S., Rehim, S. S. A., Mattiello, L., Malacaria, E., Galassi, C., Signore, M., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00733-4 · Cited by 31
Wheler, J. J., Mutch, D. G., Lager, J. J., Castell, C., Liu, L., Jiang, J., & Traynor, A. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0257 · Cited by 30
Paul, S., Chatterjee, S., Sinha, S., Dash, S. R., Pradhan, R., Das, B., Goutam, K., & Kundu, C. N. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2266572 · Cited by 29
Liu, C., Xing, W., Yu, H., Zhang, W., & Si, T. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01800-7 · Cited by 29
Moore, K. N., Hong, D. S., Patel, M. R., Pant, S., Ulahannan, S. V., Jones, S. F., Meric‐Bernstam, F., Wang, J. S.-Z., Aljumaily, R. M., Hamilton, E. P., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00835-0 · Cited by 28
Goodwin, R. A., Jonker, D. J., Chen, E. X., Kennecke, H. F., Cabanero, M., Tsao, M., Vickers, M. M., Bohemier, C., Lim, H. J., Ritter, H. D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00814-3 · Cited by 26
Hirano, T., Satow, R., Kato, A., Tamura, M., Murayama, Y., Saya, H., Kojima, H., Nagano, T., Okabe, T., & Fukami, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.001 · Cited by 25
Wang, C.-H., Baskaran, R., Ng, S. S.-C., Wang, T., Li, C., Ho, T., Hsieh, D. J., Kuo, C., Chen, M., & Huang, C. (2023) · Journal of Cancer · doi:10.7150/jca.77322 · Cited by 24
Takashima, A., Alfonso, P. G., Manneh, R., Beşen, A. A., Hong, Y. S., Cuyle, P.-J. A., Yanez, P. E., Burge, M., Yoshino, T., Kim, T. W., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114036 · Cited by 23
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue
Prabhu, L., Martin, M., Chen, L., Demir, Ö., Jin, J., Huang, X., Motolani, A., Sun, M., Jiang, G., Nakshatri, H., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.04.001 · Cited by 21
Antineoplastic Therapy in Colorectal Cancer through Proteasome Inhibition
Hochwald, S. N., Lind, D. S., Malaty, J. Z., Copeland, E. M., Moldawer, L. L., & MacKay, S. L. D. (2003) · The American Surgeon · doi:10.1177/000313480306900104 · Cited by 20
Sastre, J., Alfonso, P. G., Viéitez, J. M., Cano, M. T., Rivera, F., Zoilo, J. J. R., Salud, A., Quintero, G., Robles-Díaz, L., Safont, M. J., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100062 · Cited by 20
Self-citationClarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03916-0 · Cited by 18
Morris, V. K., Lam, M. S., Wang, X., Overman, M. J., Johnson, B., Kee, B. K., Wolff, R. A., Dasari, A. N., Zorrilla, I. R., Tam, A. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.79 · Cited by 17
Li, L., Li, R., & Wang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105707 · Cited by 16
Robbrecht, D. G. J., Doger, B., Grob, J., Bechter, O. E., de Miguel, M. J., Vieito, M., Schadendorf, D., Curigliano, G., Borbath, I., Butler, M. O., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.2524 · Cited by 15
Larson, T., Ortuzar, W. F., Bekaii‐Saab, T., Becerra, C., Ciombor, K. K., Hubbard, J. M., Edenfield, W. J., Shao, S. H., Grothey, A. F., Borodyansky, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.677 · Cited by 11
Chen, L., de Marval, P. L. M., Powell, K., Johnson, M., Falls, G., Lawhorn, B. G., Candi, A., Kilonda, A., Vanderhoydonck, B., Marchand, A., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-4964 · Cited by 11
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study
Quiñonero, F., Cepero, A. L., Urbano, D., Muñoz‐Gámez, J. A., Martín‐Guerrero, S. M., Martín‐Oliva, D., Prados, J. C., Melguizo, C., & Ortíz, R. (2021) · Journal of Biosciences · doi:10.1007/s12038-020-00135-1 · Cited by 9
Kopetz, S., Morris, V. K., O’Neil, B. H., Bridgewater, J. A., Graham, J. S., Parkes, E. E., Saunders, M. P., Asken, E., Goodwin, L., Phillips, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps3637 · Cited by 9
Kim, T. W., Lee, K.-W., Ahn, J. B., Hong, Y. S., Kim, S. Y., Kim, J. W., Kim, J., Shin, S. J., Beom, S., Kim, S. T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.1809 · Cited by 6
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.
Alese, O. B., Diab, M., Gbolahan, O. B., McCook-Veal, A., Shaib, W. L., Wu, C. S.-Y., Akce, M., Liu, Y., Lesinski, G. B., & El‐Rayes, B. F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.3579 · Cited by 6
Cecchini, M., Walther, Z., Wei, W., Hafez, N., Pilat, M. J., Boerner, S. A., Durecki, D. E., Eder, J. P., Schalper, K. A., Chen, A. P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0485 · Cited by 4
Pastor, D. M., Redman, J. M., Floudas, C. S., Lamping, E., Francis, D. C., Cordes, L. M., Marté, J. L., Schlom, J., Gulley, J. L., & Strauss, J. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.116 · Cited by 4
Grothey, A., Yoshino, T., Xu, R., Zalcberg, J., Sargent, D. J., Choti, M. A., Rutstein, M. D., Cupit, L., Kuss, I., & Cutsem, E. V. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu333.112 · Cited by 2
Safran, H. P., Dhawan, M. S., Cavalcante, L. L., de Souza, A. L., Powell, S. F., Billadeau, D. D., Giles, F. J., Münster, P. N., & Carneiro, B. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.827 · Cited by 2
Xu, R.-H., Qiu, M., Bai, Y., Wang, J., Gu, K., Yang, M. G., He, Y., Yi, C., Jin, Y., Liu, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.1802 · Cited by 1
Molecular and clinical characterization of a claudin (CLDN)-low subtype of gastric cancer (GC).
Nishijima, T. F., Kardos, J., Chai, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.67
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“A second key approach for targeting colorectal CSCs involves the suppression of specific signaling pathways that are critical for CSC maintenance and proliferation [69,71,72].”
InfluentialMengistu, B. A., Tsegaw, T., Demessie, Y., Getnet, K., Bitew, A. B., Kinde, M. Z., Berihun, A. M., Mebratu, A. S., Mekasha, Y. T., Feleke, M. G., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03558-0 · Cited by 84
Chen, Q., Shen, M., Yan, M., Han, X., Mu, S., Li, Y., Luo, L., Wang, Y., Li, S., Li, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05518-8 · Cited by 39
Cancer stem cells in focus: Deciphering the dynamic functional landscape of stemness in cancer
Nwokolo, G. C., Ganesan, T. S., Pors, K., Falconer, R. A., & Sneha, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189440 · Cited by 14
GNG2 inhibits brain metastases from colorectal cancer via PI3K/AKT/mTOR signaling pathway
Luo, C., Xiao, Z., & Yang, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-85592-0 · Cited by 10
Metadata
- Authors
- Martínez-Pérez, J., Torrado, C., Domínguez-Cejudo, M. A., & Valladares-Ayerbes, M.
- Affiliations
- Medical Oncology Department, Hospital Universitario Virgen del Rocio (HUVR), Avenida de Manuel Siurot s/n, 41013 Seville, Spain
- The University of Texas MD Anderson Cancer Center (US)
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocio (HUVR), Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Avenida de Manuel Siurot s/n, 41013 Seville, Spain
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-06-05
- Volume
- 25
- Issue
- 11
- Pages
- 6220
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172446
- OpenAlex
- W4399366851
- Cited by
- 18
- References
- 132
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- colorectal cancer, cancer stem cells, targeted therapy, metastatic colorectal cancer, adjuvant chemotherapy, fluoropyrimidine, oxaliplatin, VEGF inhibitors, EGFR inhibitors, tyrosine kinase inhibitors, immunotherapy, microsatellite instability-high, Wnt/β-catenin signaling, Hedgehog signaling, Notch signaling, TGF-β/Smad signaling, PI3K/AKT/mTOR pathway, NF-κB signaling, JAK/STAT signaling, DNA damage response, Hippo/YAP signaling, dedifferentiation, clinical trials
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
